GX BIOSYSTEMS AS has a total of 17 patent applications. Its first patent ever was published in 1993. It filed its patents most often in Canada, United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology and pharmaceuticals are HENAN HUALONG BIOLOGICAL TECH CO LTD, REFUGE BIOTECHNOLOGIES INC and ANHUI SINOBIOWAY CELL THERAPY CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 4 | |
#2 | United States | 4 | |
#3 | WIPO (World Intellectual Property Organization) | 3 | |
#4 | Australia | 2 | |
#5 | EPO (European Patent Office) | 2 | |
#6 | Brazil | 1 | |
#7 | New Zealand | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Peptides | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Bej Asim K | 9 |
#2 | Molin Soren | 9 |
#3 | Givskov Michael | 9 |
#4 | Eberl Leo | 9 |
#5 | Kristensen Claus Sternberg | 8 |
#6 | Klemm Per | 6 |
#7 | Pallesen Lars | 4 |
#8 | Sokurenko Evgeni Veniaminovic | 4 |
#9 | Hasty David Long | 4 |
#10 | Molin S Ren | 3 |
Publication | Filing date | Title |
---|---|---|
US5834233A | Method of limiting the survival of genetically engineered microorganisms in their enivronment | |
US5670370A | Biological containment | |
US5702916A | Biological Containment | |
AU1532795A | Receptor specific bacterial adhesins and their use | |
NZ274482A | Cells transformed with a truncated and/or mutated staphylococcus aureus nuclease and their use in immunological, pesticidal and environmental pollutant-degrading compositions | |
AU3949193A | A method of limiting the survival of genetically engineered microorganisms in their environment |